
BusinessLead story
Pathos AI raises $237M at a $3B valuation in Bristol Myers-led round
The Series E comes with a Bristol Myers Squibb partnership and a $55M Tempus data deal that take Pathos's AI agents from cancer into Alzheimer's.
Jaeden SchaferEditor in Chief4 min read